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Abstract
Background: Folate and vitamin B12 are keys to the correct functioning of one-carbon (1-C) metabolism. The current evidence on associations 
between 1-C metabolism biomarkers and mortality is inconclusive and generally based on younger or institutionalized populations. This study 
aimed to determine the associations between biomarkers of 1-C metabolism and all-cause and cardiovascular (CVD) mortality in the very old.
Methods: The Newcastle 85+ Study is a prospective longitudinal study of participants aged 85 at recruitment living in Northeast England. 
Baseline red blood cell folate (RBC folate), plasma vitamin B12, and total homocysteine (tHcy) concentrations were available for 752–766 
participants. Associations between biomarkers of 1-C metabolism and all-cause and CVD mortality for up to 9 years were assessed by Cox 
proportional hazard models and confirmed by restricted cubic splines.
Results: Participants with higher tHcy concentrations had higher risk of death from any cause (hazard ratio [HR] [×10 μmol/L]: 1.24, 
95% confidence interval [CI]: 1.10–1.41) and cardiovascular diseases (HR [×10 μmol/L]: 1.23, 95% CI: 1.04–1.45) than those with lower 
concentrations; and women with higher plasma vitamin B12 concentrations had increased risk of all-cause and cardiovascular mortality (HR 
[×100 pmol/L]: 1.10, 95% CI: 1.04–1.16) after adjustment for key sociodemographic, lifestyle, and health confounders.
Conclusion: Higher concentrations of tHcy in all participants and plasma vitamin B12 in women were associated with increased risk of 
all-cause and CVD mortality in the very old. This confirms findings for tHcy in younger populations but the adverse relationships between 
elevated plasma vitamin B12 concentrations and mortality in this setting are novel and require further investigation.
Keywords: “Aged, 80 and over”, One carbon metabolism, Folate.
Folate and vitamin B12 are essential for normal function of one-
carbon (1-C) metabolism. Folate provides 1-C units for de novo 
biosynthesis of purines and pyrimidines, transmethylation of homo-
cysteine to methionine and interconversions of serine and glycine 
(1). Elevated levels of homocysteine may promote endothelial dys-
function, atherothrombosis and lipid peroxidation (2). Vitamin B12 
acts as a coenzyme for methionine synthase (MS), responsible for 
the transmethylation of homocysteine to methionine and consequent 
production of S-adenosylmethionine (SAM) and methylmalonyl-
CoA mutase, which converts methylamalonyl-CoA to succinyl-CoA 
in the fatty acid synthesis pathway (1). SAM is the universal methyl 
donor for methylation of all cellular macromolecules, including 
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DNA and histones, and therefore plays a critical role in regulation 
of gene expression (1). Given the key role in 1-C metabolism, it is no 
surprise that homocysteine, folate, and vitamin B12 have been asso-
ciated with cardiovascular disease (CVD) and all-cause mortality. 
A meta-analysis pooling data from 30 randomized controlled trials 
(RCTs) reported that folic acid supplementation reduced CVD risk 
by 4% and the risk of stroke by 10% (3). Some have found that 
high concentrations of vitamin B12 were associated with all-cause 
mortality (4,5) and cancer (particularly hematological and, smoking 
and alcohol related cancers) (6,7) while others did not (8–11). It is 
hypothesized that “very high” vitamin B12 concentrations may be 
due to (i) increased release of vitamin B12 from storage, (ii) upregu-
lation of haptocorrin and transcobalamin synthesis, (iii) decreased 
clearance of vitamin B12 from plasma, and/or (iv) diminished bind-
ing affinity of vitamin B12 for transporter proteins (all of which may 
be associated with disease development) but no clear mechanism has 
been determined (12,13).
The current evidence for links between 1-C metabolism biomark-
ers and mortality is inconclusive and based on studies in younger 
or institutionalized populations. This study aimed to examine asso-
ciations between red blood cell folate (RBC folate), plasma vitamin 
B12, and total homocysteine (tHcy) concentrations at baseline, and 
all-cause and cardiovascular mortality over 9 years in a large sample 
of very old adults.
Material and Methods
The Newcastle 85+ Study
The Newcastle 85+ Study is a prospective longitudinal study of 
health trajectories and outcomes in the very old which approached 
all people turning 85 in 2006 (born in 1921), who were registered in 
participating general practices (NHS), who did not have an end-stage 
terminal illness and lived in North East England (Supplementary 
Figure 1). Study details can be found elsewhere (14).
Biomarkers of 1-C Metabolism
Forty milliliters of blood were drawn from the antecubital vein after 
an overnight fast and 95% of the samples were sent within 1 hour 
to the laboratory. tHcy, RBC folate, and plasma vitamin B12 con-
centrations were determined by immunoassay at baseline (15). tHcy, 
RBC folate, and plasma vitamin B12 concentrations were available 
for 766 (74% response rate [766/1042]), 752 (72% response rate 
[752/1042]), and 753 (72% response rate [752/1042]) participants, 
respectively, and were categorized into quartiles (Supplementary 
Methods). tHcy concentrations were also categorized into <11, 
11–15, and >15 µmol/L (16) and plasma vitamin B12 into <148, 
148–500, and >500 pmol/L. A plasma vitamin B12 concentration 
<148 pmol/L is commonly used to diagnose deficiency (17) while a 
concentration >600 pmol/L is used to identify high plasma vitamin 
B12 concentrations (6,7). Further, an upper limit of 569 pmol/L is 
used by the department of clinical biochemistry at the Newcastle 
Royal Victoria Infirmary where samples were analyzed (18). 
However, because of the low number of participants with plasma 
vitamin B12 concentrations >600 pmol/L (n = 36) and >569 pmol/L 
(n = 41), >500 pmol/L (n = 53) was used.
All-Cause and Cardiovascular Mortality
Information on dates and cause of death (International classifica-
tion of diseases and related disorders, 10th revision [ICD-10]) were 
obtained from the Health and Social Care Information Service (now 
NHS Digital), UK (19). Deaths coded as I00-I99 (Chapter IX of the 
ICD-10) were used to determine CVD mortality (19). The time to 
event of interest (all-cause mortality or cardiovascular-specific mor-
tality) was calculated as the time between blood draw (2006–2007) 
and time of death (censored on April 28, 2015). Mortality follow-up 
was conducted over 9 years.
Statistical Analysis
Details for descriptive statistical analysis and normality assessment 
are shown in Supplementary Methods.
Longitudinal associations between 1-C metabolism biomarkers 
(continuous, quartiles, and cut-offs) and mortality (all-cause and 
CVD) were assessed with Kaplan–Meier curves (unadjusted) and 
Cox proportional hazards models. Briefly, variables used in the mod-
els were chosen for their clinical relevance and from univariate analy-
ses while efforts were made not to overfit the data. Model 1 was not 
adjusted; Model 2 was adjusted for sex and education; Model 3 was 
additionally adjusted for disease count and Standardized Mini-Mental 
State Examination score (SMMSE). The tHcy Model 3 was addition-
ally adjusted for renal impairment; Model 4 was also adjusted for 
body mass index (BMI), physical activity, smoking, alcohol intake; 
and Model 5 was further adjusted for the other 1-C metabolism bio-
markers (eg, the RBC folate model was adjusted for plasma vitamin 
B12 and tHcy concentrations). Details of the health assessment and 
disease count are shown in the Supplementary Methods.
To confirm findings and to assess the linearity of relationships, 
restricted cubic splines were fitted to the final models with five knots at 
default locations based on quantiles. For example, the quantiles for the 
tHcy model for all participants were 10, 14, 17, 21, and 32 µmol/L; for 
the RBC folate model were 370, 639, 868, 1,205, and 2,244 nmol/L; 
and 102, 178, 232, 307, and 584 pmol/L for plasma vitamin B12. 
Multicollinearity was checked with tolerance, variation inflation fac-
tor (VIF) and eigenvalues. The proportional hazards (PH) assump-
tion for every Cox regression model was tested by visual inspection 
of plots for log(−log[survival] vs log[time]) and Schoenfeld residuals 
versus time. All models used met the PH assumption. In the sensitivity 
analysis, models were further adjusted for: alanine aminotransferase 
(ALT), alkaline phosphatase, and bilirubin concentrations; or for high 
sensitivity C-reactive protein (hs-CRP); or folic acid/vitamin B12 sup-
plement users; or housing status; or pyridoxal phosphate (vitamin 
B6); or total cholesterol. The association between plasma vitamin B12 
and all-cause mortality in women by <1 and >1 year of follow-up was 
also assessed by Cox regression models (unadjusted).
Analyses were carried out in IBM SPSS statistics v22.0 except for 
inspection of the Schoenfeld residuals and plotting restricted cubic 
splines where R v3.2.2 (packages “survival” and “rms”) was used. 
p <.05 was used to broadly assess statistical significance and point 
estimates (with confidence intervals) to assess clinical significance.
Results
Over the 4,082 person-years of follow-up, 73% (n  =  564) (13.8 
deaths per 100 person-years) of those that had 1-C metabolism bio-
markers measured at baseline died. Of these, 53% (n = 299) (7.3 
deaths per 100 person-years) died from CVD. The percentage of 
participants who died from CVD during the first year of follow-up 
was similar (49%) to the whole duration of follow-up. The median 
survival time was 5.5 (IQR: 2.7–8.0) years.
Data on biomarkers of 1-C metabolism were more likely to be 
missing from women (11%) than men (5%), from those who lived in 
institutions (26%) than in the community (7%), from those who had 
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low physical activity (12%) than high physical activity (3%), who 
were not alcohol drinkers (11%) than those who were (3%) and 
who had a lower score in the SMMSE. A flowchart of the recruit-
ment and retention profile by 1-C metabolism biomarkers availabil-
ity over the study period is presented in Supplementary Figure 1.
Total Homocysteine
There were more men, more renally impaired participants and with 
lower concentrations of ALT in higher quartiles of tHcy. tHcy quar-
tiles were inversely associated with RBC folate and plasma vitamin 
B12 concentrations (Table 1).
Survival was longest in Q1 of tHcy (median: 7.1, 95% confidence 
interval [CI]: 5.9–8.2 years) and lowest in Q4 (median: 4.0, 95% 
CI: 3.3–4.7) in unadjusted models (Figure  1 and Supplementary 
Table 1). These differences seemed to emerge after the first year of 
follow-up (<1 year of follow-up—hazard ratio [HR]: 1.10, 95% CI: 
0.87–1.38, p =  .441 and >1 year—HR: 1.36, 95% CI: 1.21–1.52, 
p < .001; data not shown). For every 10 µmol/L increase in tHcy 
concentrations the risk of all-cause mortality increased by 24% (HR: 
1.24, 95% CI: 1.10–1.41, p < .001) in all participants over 9 years 
after adjustment for socioeconomic and health variables, RBC fol-
ate, and plasma vitamin B12 (Supplementary Table 2). Visual inspec-
tion of restricted cubic splines of the relationship between tHcy 
and all-cause mortality confirmed these findings (Figure 2). Results 
were similar for cardiovascular mortality (Supplementary Tables 2 
and 4, Figures 1 and 2, and Supplementary Figures 2 and 3). All 
relationships between tHcy and mortality were linear (Figure 2 and 
Supplementary Figure 3). Participants with tHcy concentrations <11 
(HR: 0.61, 95% CI: 0.42–0.88, p = .008) or 11–15 (HR: 0.78, 95% 
CI: 0.63–0.97, p = 0.028) µmol/L had a lower risk of all-cause mor-
tality than those with >15 µmol/L (Table  3). Results were similar 
using quartiles of tHcy concentration (Supplementary Table 3).
Red Blood Cell Folate
Those in higher quartiles of RBC folate had a slightly higher chronic 
disease count and more history of CVD than those in lower quartiles 
(Table 1).
Hazard ratios for all-cause and cardiovascular mortality in RBC 
folate models in all participants were not significant (Supplementary 
Tables 2–4, Figure 2, and Supplementary Figures 2 and 3), stratified 
by sex or length of follow-up (ie, <1 and >1 year; data not shown). 
All relationships between RBC folate and mortality were linear 
(Figure 2 and Supplementary Figure 3).
Plasma Vitamin B12
There were no significant differences in the prevalence of chronic 
diseases or risk factors between quartiles of plasma vitamin B12 
(Table  1). Individuals in different quartiles of plasma vitamin 
B12 concentration had similar survival rates for all-cause mortal-
ity (Supplementary Tables 1 and 3 and Supplementary Figure  2). 
However, there was a trend for increased hazard ratios in the top 
quartile of plasma vitamin B12 (>325 pmol/L) compared to the low-
est quartile (<170 pmol/L) for cardiovascular mortality (HR: 1.46, 
95% CI: 1.00–2.13, p = .048) (Supplementary Table 3).
There was a significant sex × plasma vitamin B12 interaction 
(HR: 1.09, 95% CI: 1.01–1.19, p  =  .036) therefore models were 
Table 1. Population Characteristics in the Newcastle 85+ Study by Quartiles of Total Homocysteine, RBC Folate, and Plasma Vitamin B12
Total homocysteine (µmol/L)
Q1 (<13.5) Q2 (13.5–16.7) Q3 (16.7–21.4) Q4 (>21.4) p*
Men (%, n) 32 (61) 32 (62) 50 (96) 43 (83) <.001
Red blood cell folate (nmol/L) 1,272 (896–1,748) 940 (675–1,279) 779 (573–1,084) 680 (477–898) <.001
Plasma vitamin B12 (pmol/L) 297 (225–430) 230 (185–303) 225 (161–293) 186 (134–262) <.001
Physical activity (high) (%, n) 38 (72) 34 (65) 38 (72) 31 (58) .02
Renal impairment (%, n) 8 (15) 15 (29) 22 (41) 51 (98) <.001
ALT (U/L) 18 (15–23) 17 (14–21) 16 (13–20) 15 (12–19) <.001
Red blood cell folate (nmol/L)
Q1 (<612) Q2 (612–870) Q3 (870–1,280) Q4 (>1,280) p*
Plasma vitamin B12 (pmol/L) 201 (135–280) 216 (159–275) 259 (193–371) 278 (205–391) <.001
Total homocysteine (µmol/L) 19.9 (16.3–24.6) 18.3 (14.9–22.9) 15.6 (13.0–19.6) 13.8 (11.1–17.4) <.001
Disease count (mean, SD) 2.0 (1.2) 2.3 (1.3) 2.4 (1.2) 2.4 (1.2) .01b
History of cardiovascular disease (%, n) 45 (84) 57 (108)  66 (123) 63 (119) <.001
Plasma vitamin B12 (pmol/L)
Q1 (<170) Q2 (170–232) Q3 (232–325) Q4 (>325) p*
Red blood cell folate (nmol/L) 683 (479–992) 838 (605–1,159) 913 (690–1,393) 1058 (745–1,608) <.001
Total homocysteine (µmol/L) 19.7 (15.9–25.1) 17.3 (14.5–21.8) 15.9 (13.3–19.8) 13.9 (11.1–18.2) <.001
Disease count (mean, SD) 2.2 (1.3) 2.4 (1.2) 2.2 (1.2) 2.3 (1.2) .51b
ALT (U/L) 16 (13–20) 16 (13–21) 17 (14–21) 17 (14–22) .03
Notes: Continuous variables are presented as medians and interquartile range unless otherwise stated. History of cardiovascular disease includes cardiac, cere-
brovascular, and peripheral vascular diseases. ALT = alanine aminotransferase; Q = quartile; SD = standard deviation.
*Chi-squared test (χ2) or Kruskal–Wallis test.
bOne-way ANOVA. 
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stratified by sex (Table 2). Using plasma vitamin B12 as a continuous 
variable, for every increase in 100 pmol/L, the risk of all-cause and 
cardiovascular mortality increased by 10% in women (HR: 1.10, 
95% CI: 1.04–1.16, p < 0.001 and HR: 1.10, 95% CI: 1.02–1.18, 
p = .016, respectively) but not in men (Table 2). Visual inspection of 
restricted cubic spline curves confirmed these findings and showed 
a linear relationship with mortality (except for cardiovascular 
mortality in women, p  =  .016; Figures 2 and 3). The association 
between plasma vitamin B12 concentration and mortality in women 
remained significant if analyses were stratified by <1 and >1 year of 
follow-up (Figure 3 and Supplementary Table 5).
Seventeen percent (n  =  128) of participants had plasma vita-
min B12 concentrations <148 pmol/L, 76% (n = 569) had 148–500 
pmol/L and 7.4% (n  = 56) had >500 pmol/L. Participants with a 
plasma vitamin B12 >500 pmol/L were at 40% higher risk of all-
cause mortality than those with 148–500 pmol/L (HR:1.41, 95% CI: 
1.02–1.95, p = .039) (Figure 1 and Table 3).
Discussion
During the 4,082 person-years of follow-up, 73% of the participants 
died and 53% of these deaths were due to CVD. In this longitu-
dinal cohort study of more than 750 participants ≥85  years with 
9 years mortality follow-up, men and women with higher baseline 
tHcy concentrations and women with higher plasma vitamin B12 
concentrations (in particular those >500 pmol/L) were at higher risk 
of death from all-causes and from CVD after adjustment for soci-
odemographic, lifestyle, and health variables.
Evidence from observational studies confirm our findings 
that tHcy concentrations are predictive of CVD and/or mortality 
(2,5,8,11,20–22). Folate donates methyl groups for homocysteine 
transmethylation to form methionine and, typically, folic acid sup-
plementation lowers homocysteine concentrations by 13%–25% 
(23,24). Although it is still debatable whether homocysteine is a 
causal factor or a marker of CVD and mortality (25), others have 
shown that supplementation with folic acid decreased the risk of 
CVD, especially stroke (3). There was no significant association 
between RBC folate concentration and all-cause and cardiovascular 
mortality—a finding, similar to some studies (26–31) but not oth-
ers (3,32–34). To the best of our knowledge, the effect of folate on 
all-cause and cardiovascular mortality has not been investigated in 
a very old population and the possibility of an age group-specific 
effect cannot be discounted. The low baseline tHcy concentration 
or already high folate concentration is frequently pointed out as a 
limiting factor to detect an effect. However, 57% of the participants 
in the Newcastle 85+ Study had hyperhomocysteinemia and still no 
effect was observed (ie, if lowering tHcy is the biological mechanism 
behind the beneficial effect of folate on mortality).
Figure 1. Kaplan–Meier plot of the probability of survival for all-cause (A) and 
cardiovascular mortality (B) by total homocysteine quartiles, and all-cause 
mortality in women by plasma vitamin B12 quartiles (C) and reference ranges 
in women (D). Censoring is indicated by crosses.
Figure  2. Restricted cubic spline curves of dose–response relationship 
between total homocysteine (A), red blood cell folate (B) and plasma vitamin 
B12 (C), and all-cause mortality hazard ratios from the fully-adjusted Cox 
regression models in Supplementary Table 2 and Table 2.
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Our study confirms findings from others where high plasma vita-
min B12 was associated with greater all-cause mortality (4,5) and 
cancer diagnosis/mortality (6,7). Arendt and colleagues (6) identified 
more than 300,000 people from Danish medical registries not receiv-
ing supplemental vitamin B12 and with initial plasma vitamin B12 
concentrations >200 pmol/L; categorized them into 200–600, 601–
800, and >800 pmol/L and found that cancer incidence increased 
with higher vitamin B12 concentrations. This effect was more pro-
nounced for hematological, smoking and alcohol-related cancers, 
and during the first year of follow-up (6). In a further retrospect-
ive case–control study of 25,017 patients with cancer diagnosis and 
plasma vitamin B12 concentrations >200 pmol/L (measured before 
diagnosis), the same research team reported that patients with a can-
cer diagnosis who had vitamin B12 concentrations greater than 600 
pmol/L had higher risk of mortality than those with concentrations 
of 200–600 pmol/L (7).
Elevated plasma vitamin B12 concentrations have been found 
in patients with liver, renal, autoimmune, cancers, and infectious 
diseases (12). Such diseases may disrupt the uptake of vitamin 
B12 by the liver, the biggest reservoir of vitamin B12 in the body. 
Alternatively, increased hepatocyte turnover/damage may lead to 
greater leakage of liver vitamin B12 (12,35), resulting in higher lev-
els of vitamin B12 in plasma. High plasma vitamin B12 has also 
been associated with hematological malignancies (12). It is believed 
that an increase in the number of leukocytes increases haptocor-
rins’s production and release into the circulation (12). An increase 
in haptocorrin and subsequent binding of vitamin B12 could lead 
to reduced holotranscobalamin binding, and hence reduced cellular 
uptake of vitamin B12 (35). Therefore, it is also possible that, para-
doxically, functional deficiency of vitamin B12 occurs concomitantly 
with elevated plasma vitamin B12 concentrations (35). All of these 
explanations could account for our findings.
To determine if elevated plasma vitamin B12 was due to liver 
damage, models were further adjusted for alanine aminotransferase, 
alkaline phosphatase, and bilirubin; and to determine if it was due to 
other nonliver related conditions, models were adjusted for hs-CRP. 
Findings were not significantly different in either of the models. Other 
sensitivity analyses also did not change the overall conclusions.
The large number of very old adults, the extensive health 
assessment, the socio-demographic representativeness for the 
United Kingdom and the rapid processing of blood samples after 
Table 2. Hazard Ratios for All-Cause and Cardiovascular Mortality by Plasma Vitamin B12 (×100 pmol/L) in All Participants, Men, and Women
All Men Women
HR 95% CI p HR 95% CI p HR 95% CI p
All-cause mortality
Model 1 1.05 1.01–1.09 .008 1.00 0.94–1.06 .989 1.10 1.05–1.16 <.001
Model 2 1.05 1.01–1.09 .016 1.00 0.94–1.06 .940 1.10 1.05–1.15 <.001
Model 3 1.05 1.01–1.09 .021 0.98 0.92–1.05 .634 1.11 1.06–1.17 <.001
Model 4 1.05 1.01–1.09 .022 1.00 0.93–1.07 .980 1.10 1.04–1.15 <.001
Model 5 1.05 1.01–1.10 .015 1.01 0.94–1.08 .879 1.10 1.04–1.16 <.001
Cardiovascular mortality
Model 1 1.05 1.00–1.11 .069 1.01 0.93–1.09 .863 1.09 1.02–1.17 .015
Model 2 1.05 0.99–1.10 .091 1.01 0.93–1.09 .821 1.09 1.02–1.17 .017
Model 3 1.05 1.00–1.11 .073 1.01 0.92–1.09 .915 1.10 1.03–1.18 .007
Model 4 1.06 1.00–1.12 .055 1.01 0.93–1.10 .821 1.09 1.02–1.18 .016
Model 5 1.06 1.00–1.12 .063 1.00 0.91–1.10 .950 1.10 1.02–1.18 .016
Note: Model 1 is not adjusted; Model 2 is adjusted for sex and education; Model 3 is additionally adjusted for disease count and standardized Mini-Mental State 
Examination score; Model 4 is also adjusted for body mass index, physical activity, smoking, and alcohol intake; Model 5 is further adjusted for total homocysteine 
and red blood cell folate concentrations. CI = confidence interval; HR = hazard ratio.
Figure  3. Restricted cubic spline curves of dose–response relationship 
between plasma vitamin B12 and all-cause mortality hazard ratios for men 
and women (A) from fully-adjusted Cox regression models from Table 2, and 
by <1 and >1 year of follow-up (B) from Supplementary Table 5.
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venepuncture are all considerable strengths of this study. Further, 
unlike previous literature the majority of the participants lived in 
the community. However, our study does have limitations. Given 
that all participants were 85  years at recruitment, an age when 
mortality rates are high, it is impossible to exclude completely any 
survival bias due to selective survivability. The use of holotransco-
balamin, which measures only the metabolically active fraction of 
vitamin B12 (while the immunoassay used measures total circulat-
ing vitamin B12) would have likely yielded different associations 
with mortality. Due to the insufficient number of deaths in the first 
year of follow-up, models stratified by length of follow-up could 
not be fully adjusted and the hypothesis that (i) 1-C metabolism 
biomarkers reflect vitamin deficiency and predict long-term mortal-
ity or (ii) 1-C biomarkers are markers of disease severity and pre-
dict short-term mortality, could not be fully investigated. However, 
the association between tHcy and mortality seemed to emerge after 
the first year of follow-up while the association between plasma 
vitamin B12 and mortality was stronger during the first year of 
follow-up.
In summary, elevated concentrations of tHcy in men and women 
and plasma vitamin B12 in women were associated with increased 
risk of mortality in the very old. This confirms findings for tHcy but 
the finding of adverse relationships between elevated plasma vitamin 
B12 concentrations and mortality in mostly community-dwelling 
very old adults is novel and requires further investigation.
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